Competition and Markets Authority says companies abused position by raising prices of epilepsy drug by up to 2,600%

The competition watchdog has accused Pfizer and Flynn Pharma of breaching UK and European law by ramping up the cost of an epilepsy drug given to more than 50,000 British patients by as much as 2,600%.

The Competition and Markets Authority (CMA) said its provisional view was that the companies abused a dominant position by charging “excessive and unfair” prices for phenytoin sodium capsules.

Continue reading…
Source: The Guardian Circular Economy RSS